Pipeline | Indication | Status | Brief MOA | |
---|---|---|---|---|
AZBT51105 T Cell Vaccine |
PDF다운 | Cancer Vaccine / Virus Vaccine |
First-in-Class |
Using immunotherapy to recognize and eliminate |
AZBR52209 siRNA Delivery Peptide |
PDF다운 | RNAi Therapy |
First-in-Class |
Prevent disease-causing mutations of protein by targeted gene inhibition |
AZBE53206 ER Targeting Peptide |
PDF다운 | ER Stress related Disease |
First-in-Class |
Intervening in ER stress and modulating signaling components of the UPR |
As of 2022.Q2
Pipeline | 2021 | 2022 | 2023 | 2024 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | |
AZBT51105 |
In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
||||||||||||||||
AZBR52209 |
Target analysis In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
||||||||||||||||
AZBE53206 |
Target analysis In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
- Prediction of CPP sequence and LNPs for Efficient Drug Delivery into Specific Organelles